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Abstract 
The MTT/MTS in vitro cell proliferation assay is one of the most widely used assays for evaluating 
preliminary anticancer activity of both synthetic derivatives and natural products and natural product 
extracts. The highly reliable, colorimetric based assay is readily performed on a wide range of cell lines. 
This assay gives an indication of whole cell cytotoxicity; however, to determine the exact molecular target 
further assays need to be performed. Of these, kinase inhibition assays are also one of the most 
widespread enzyme inhibition screening assays performed. Kinases are enzymes that play a key role in a 
number of physiological processes and their inhibitors have been found to exhibit anticancer activity 
against various human cancer cell lines. Herein, we describe the methods for performing both in vitro 
MTT/MTS cytotoxicity and kinase enzyme inhibition assays. These are two of the most useful anticancer 
screening techniques available that are relatively economical and can be easily and routinely performed in 
the laboratory to characterize anticancer activity. Both assays are highly versatile and can be modified to 
test against targeted disease processes by using specific kinase enzymes or cell lines. 
Keywords 
MTS/MTT assays, Cytotoxicity, Anticancer activity, Human cancer cell lines, Enzyme inhibition, Kinases, 
CMMB 
Disciplines 
Medicine and Health Sciences | Social and Behavioral Sciences 
Publication Details 
McCauley, J., Zivanovic, A. & Skropeta, D. (2013). Bioassays for anticancer activities. Methods in 
Molecular Biology, 1055 191-205. 
This journal article is available at Research Online: https://ro.uow.edu.au/smhpapers/1396 
    Anticancer Bioassays 1
Bioassays for Anticancer Activities 
Janice McCauley,1,2 Ana Zivanovic1,3 D. Skropeta*1,3 
1 School of Chemistry, University of Wollongong, Wollongong, 2522, NSW Australia 
2
 Shoalhaven Marine and Freshwater Centre, School of Biological Sciences 
University of Wollongong, Shoalhaven Campus, 2541, NSW, Australia.  
3
 Centre for Medicinal Chemistry, University of Wollongong, Wollongong, 2522, 
NSW Australia 
 
Running head: Anticancer Bioassays 
Corresponding Author*  
Danielle Skropeta 
Tel: 02 4221 4360 
Fax: 02 4221 4287   
Email: skropeta@uow.edu.au  
 
    Anticancer Bioassays 2
Bioassays for Anticancer Activities 
Janice McCauley, Ana Zivanovic and Danielle Skropeta 
 
Summary 
The MTT/MTS in vitro cell proliferation assay is one of the most widely used assays for evaluating 
preliminary anticancer activity of both synthetic derivatives and natural products and natural product 
extracts. The highly reliable, colorimetric based assay is readily performed on a wide range of cell 
lines. This assay gives an indication of whole cell cytotoxicity, however to determine the exact 
molecular target further assays need to be performed. Of these, kinase inhibition assays are also one of 
the most widespread enzyme inhibition screening assays performed. Kinases are enzymes that play a 
key role in a number of physiological processes and their inhibitors have been found to exhibit 
anticancer activity against various human cancer cell lines. Herein, we describe the methods for 
performing both in vitro MTT/MTS cytotoxicity and kinase enzyme inhibition assays. These are two of 
the most useful anticancer screening techniques available that are relatively economical and can be 
easily and routinely performed in the laboratory to characterise anticancer activity. Both assays are 
highly versatile and can be modified to test against targeted disease processes by using specific kinase 
enzymes or cell lines.  
Key words: MTS/MTT assays, cytotoxicity, anticancer activity, human cancer cell lines, 
enzyme inhibition, kinases 
 
Introduction   
A goal of many natural product chemistry and organic synthesis laboratories is 
ultimately drug discovery. An important aspect of the drug development process is 
testing both natural products and synthesised compounds for bioactivities that are 
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involved in targeted diseases processes. Cancer is a general term to define a number 
of diseases that are characterised by the uncontrolled proliferation of cells resulting 
from the disruption or dysfunction of regulatory signaling pathways that are normally 
under tight control (1-2). Cancer can spread rapidly and invade other tissues and 
organs and different cancers are recognized to have unique characteristics or markers 
(3).  
To assess for preliminary anticancer activity in terms of cell viability, the 
MTT and MTS in vitro cytotoxicity assays are considered two of the most economic, 
reliable and convenient methods. This is based on their ease of use, accuracy and 
rapid indication of toxicity (4), as well as their sensitivity and specificity (5). Both 
assays are in vitro whole cell toxicity assays that employ colorimetric methods for 
determining the number of viable cells based on mitochondrial dehydrogenase 
activity measurement and differ only in the reagent employed. In the MTT assay, 3-
(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide is bioreduced by 
dehydrogenase inside living cells to form a coloured formazan dye, while in the MTS 
assay, a similar bioconversion takes places utilising 3-(4,5-dimethylthiazol-2-yl)-5-(3-
carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium, inner salt and an electron 
coupling reagent (phenazine ethosulfate) PES (Fig. 1).  
The MTT assay requires the addition of solubilising agents to dissolve the 
insoluble formazan product formed, while the MTS assay generates a water-soluble 
formazan product, thus simplifying the assay. The number of viable cells is measured 
through colorimetry and works on the principle that the mitochondrial dehydrogenase 
enzymes which produces NADH or NADHP, reduces the colourless tetrazolium salt 
into a coloured aqueous soluble formazan product by the mitochondrial activity of 
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viable cells at 37°C (Fig. 1). The quantity of the coloured product is directly 
proportional to the number of live cells in the culture since the MTT/MTS reagent can 
only be reduced to formazan by metabolically active cells.  
 




property.	The MTT and MTS assays assess for toxicity to the particular cell under 
investigation (not anticancer activity per se). Therefore, most researchers screen for 
cytotoxicity against either murine or human cancer cell lines, as well as against a 
normal cell line such as peripheral blood lymphocytes. A selectivity index of the 
compound for cancer cells over normal cells can then be determined. It is also 
advisable to confirm MTS/MTT results with qualitative observations under the 
microscope of the cell morphology both before and after the assay. This can often 
assist in identifying potential modes of actions and deciding which further assays 
should be performed such as caspase activation, assessing stage of cell cycle arrest 
and microtubule stabilisation or destabilisation (6).      
In addition to performing MTT or MTS assays against specific cell types, 
many researchers also submit their compounds to screening by the National Cancer 
Institute (NCI). The NCI offers a rapid in vitro primary anticancer drug screen to 
support cancer researchers worldwide (7). The screen, which is performed at no cost 
to the researcher other than shipping of their sample, consists of a panel of 60 
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different human tumour cell lines from several cancer types including leukemia, 
melanoma and cancers of the lung, colon, brain, ovary, breast, prostate and kidney. 
The NCI60 screen tests the degree of growth, inhibition or cytotoxicity of a 
compound against each cell line over a range of concentrations to generate a 
characteristic profile or fingerprint of cellular response (8). A computer program 
(COMPARE) is used to assess the pattern of response across the cell lines, which can 
point towards a likely mechanism of action or identify compounds with unique modes 
of activity and/or selectivities for specific cell types. Operational details are provided 
by the NCI Developmental Therapeutics Program (DTP) and can be found at 
http://dtp.nci.nih.gov and for information regarding the submission of compounds for 
testing in the NCI screens see 
http://dtp.nci.nih.gov/docs/misc/common_files/submit_compounds.html (9). Only 
pure compounds are screened in the assay and the supplier of the sample is required to 
provide the molecular structure of any compounds submitted, which are then 
reviewed and considered for testing.  
The above assays are whole cell assays, however, often a researcher will want 
to determine activity against a specific molecular or cellular target in order to confirm 
the mechanism of action and to assess for selectivity towards different targets and any 
off-target effects. This can be achieved using in vitro inhibition assays against either 
purified enzymes or cell-free extracts enriched in the enzyme target of interest. One 
such anticancer screening method that can be easily and routinely performed in the 
laboratory in low-, medium- or high-throughput format is protein kinase inhibition 
(10). After G protein-coupled receptors (GPCRs), protein kinases are the second most 
important anticancer drug target being pursued today.   
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Unlike MTS-type assays, which are cell based, these assays are based on 
detecting the degree to which the potential drug compound can inhibit an enzyme’s 
activity. Most drugs used today demonstrate their bioactivity by acting as either 
receptor antagonists or as enzyme inhibitors. Enzymes are popular drug targets as 
they play a significant role in a number of disease processes and are susceptible to 
inhibition by small drug-like molecules (11). 
Protein kinases are an abundant group of enzymes in the human body with 
approximately 518 different protein kinases encoded in the human genome (12). 
Kinases catalyse the chemical transfer of a phosphate group from a high energy 
molecule such as adenine triphosphate (ATP) to a hydroxyl-containing substrate such 
as serine, threonine and tyrosine, and are divided into different families based on their 
selectivity for these amino acids.  
As one of the most abundant groups of enzymes in the human body, protein 
kinases are important in almost every major pathway in eukaryotic cells. They play a 
central role in the regulation of cellular activities and in signal transduction in signal 
transmission pathways. Moreover, kinases have important roles in metabolism, cell 
growth, apoptosis, immune response, gene expression, oncogenesis, cell 
differentiation and proliferation, metabolism, DNA damage repair and cell motility 
(2). As a result, the deregulation of kinases has been identified to be the main cause in 
an increasing list of diseases (13). An estimated one-third of pharma drug discovery 
programs now focus on targeting cancer-related kinases with the aim of developing 
potent and selective inhibitors with lower side effects than treatments that 
traditionally focus on DNA and chromosome regulation (14-17). An example of a 
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kinase inhibitor that has successfully proceeded onto the pharmaceutical market is 
Imitinib (Gleevec, Novartis) which is a tyrosine kinase inhibitor that has dramatically 
improved the prognosis for sufferers of chronic myeloid leukaemia after being the 
first small-molecule kinase inhibitor to be approved for human use (13).  
c-AMP Dependent protein kinase A (protein kinase A, PKA) is an enzyme 
involved in the phosphorylation of a wide range of proteins, ion channels and 
transcription factors (18). It has been demonstrated to regulate a number of 
physiological processes including cardiovascular function, steroid biosynthesis, 
reproductive function, myogenesis, adipocyte metabolism, exocytotic processes and 
immune function (19-20). PKA was also found to play a key role in memory 
processes (21). The  cAMP-PKA pathway has been linked to the promotion of 
malignant phenotypes of head and neck squamous cell carcinoma (22) and 
demonstrated to be activated in a range of tumours (23). Conversely, PKA inhibitors 
have been found to display both in vitro and in vivo anti-tumour activity against 
various human cancer cell lines and to enhance monocyte function in HIV-infected 
patients (24). Thus, it is becoming increasingly apparent that the ability to selectively 
inhibit PKA provides a new way of potentially modulating cancer, immune function, 
and memory disorders such as Alzheimer’s disease, Parkinson’s disease and 
schizophrenia (19,21,25).  
Herein, we describe methods for performing both the MTT/MTS cell 
proliferation cytotoxicity assay and for screening against the enzyme PKA. Both 
methods are widely used in our laboratory (6,26-27).  
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2. Materials 
Carry out all procedures at room temperature unless otherwise specified. 
2.1 Protein kinase assay  
This protocol is for the analysis of 14 samples per plate – each sample is run twice at 
100 μg/mL and in triplicate. This gives six data points per % inhibition reading. 
Alternatively, 14 samples can be run once at two different concentrations (100 μg/mL, 
1 μg/mL) in triplicate. This will give three data points per % inhibition reading (adjust 
protocol accordingly). The volumes provided in this protocol are intended for a 96-
well plate. The actual volumes used can be adjusted as needed. 
1. Prepare sample solutions: Prepare a 5 mg/mL stock solution of sample in 
100% dimethyl sulfoxide (DMSO). 
2. Sample dilution: Make 1 mL of a 1 mg/mL secondary stock solution (in 20% 
DMSO) of the sample by taking 200 μL of the above 5 mg/mL stock and 
adding 800 μL of Milli Q water. During the assay, this will be diluted by 1:10 
to give a final concentration of 100 μg/mL in 2% DMSO [see Notes 1 & 2]. 
3. Prepare kinase reaction buffer: Dissolve 48.5 mg of 
tris(hydroxymethyl)aminomethane (Tris), 19.0 mg of magnesium chloride 
(MgCl2) and 1.0 mg of bovine serum albumin (BSA) in 2 mL of ultra-pure 
H2O and then make up to 10 mL in a falcon tube. Adjust the pH to 7.5 using 
aqueous hydrochloric acid (HCl) if required. This will make 10 mL of reaction 
buffer that is sufficient for 1 x 96-well plate (i.e. 45 μL x 96 wells = 4.3 mL, 
plus 5 mL for adenosine triphosphate (ATP) stock) [see Note 3]. 
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4. Enzyme preparation: The PKA enzyme (Promega) used herein is supplied in 
buffer as 2500 units at 114 units/µL. Dissolve whole contents of tube 
containing enzyme in a total of 2 mL of kinase reaction buffer (see step 3 
above). Aliquot out 10 x 200 μL of this solution into labeled Eppendorf tubes 
and store at -70 °C, to give 250 units of activity per tube. The assay described 
herein utilises 2.50 units per well, i.e. 2.50 units x 96 wells = 240 units in 
total. Thus the supplied enzyme will enable testing of 10 x 96-well plates [see 
Note 4]. 
5. Kemptide (PKA) specific substrate (Promega, Australia) (10 mg/mL). The 
substrate is used as supplied and stored at -20 ºC [see Note 5]. 
6. Prepare ATP solution: Label 3 tubes: ATP stock 1, ATP stock 2 and ATP 
stock 3 (the last one is used in the assay). Weigh 5.51 mg of ATP and make up 
to 500 μL with kinase reaction buffer to give a 20 mM solution of ATP (stock 
1). Take 100 μL of ATP stock 1 and dilute to 500 μL in kinase reaction buffer 
to give a 4 mM solution. Take 15 μL of the ATP stock 2 and dilute to 3000 μL 
in kinase reaction buffer to give a 20 μM solution. This last solution is used in 
the assay to give a final concentration of 10 μM [see Note 6]. 
7. 96-well opaque white (non-sterile) plates  (Corning #3912). 
8. Micropipettes. 
9. Luminometer compatible for 96-well plates. 
10. 20% DMSO solution: Add 800 μL of distilled water to 200 μL of pure 
DMSO. 
11. A known kinase inhibitor standard reference for positive control, e.g.  
staurosporine, H-9 or H-89 (Sigma-Aldrich) [see Note 7]. 
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12. Kinase-Glo® Reagents:  Kinase-Glo® Buffer and Kinase-Glo® Substrate 
(Promega Corporation, Australia). Store at -20°C. 
 
2.2 MTS assay  
Plates containing compound dilutions should be discarded in cytotoxic waste bins. All 
pipette tips that came into contact with the test compounds should also be disposed of 
in cytotoxic waste bins  
1. Sample preparation: Prepare a 4 mg/mL stock solution of sample in DMSO. 
2. MTS reagent: Should be stored at -20 ºC for long-term storage and protected 
from light. Reagent should be warmed up to room temperature before use in 
the assay. 
3. RPMI tissue culture medium containing 5% fetal bovine serum (FBS) [see 
Note 8].  
4. Stock cultures of cells should be maintained in RPMI medium containing 5% 
FBS (fetal bovine serum).  
5. Clear, sterile 96-well microplates. 
6. Trypan blue solution (0.4%, liquid, sterile-filtered, suitable for cell culture). 
7. Dimethyl sulfoxide (DMSO). 
8. Human, leukemic, monocyte-like, histolytic lymphoma (U937) and human, 
metastatic breast adenocarcinoma (MDA-MB-231) cancer cell lines, or other 
cell lines as required [see Note 9] 
9.  Haemocytometer. 
10. Centrifuge. 
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11. Sterile incubator. 
12. UV spectrophotometer compatible for 96-well plate. 
 
3. Methods 
The kinase assay described here utilises the Kinase-Glo® Luminsecent Kinase Assay 
Platform from Promega and is performed according to the manufacturer’s instructions 
(28) with minor modifications as used in our laboratory. The method below is 
relevant to screening against PKA, however a wide range of kinases can be used in 
this assay including GSK-3β, PI3K, Src and MAPK (29,28). In theory, potentially any 
kinase could be used, provided the appropriate substrate is also utilised.	
3.1 Kinase Assay  
1. To wells A/F1‐12	of a 96-well plate, add 5 μL of the 1 mg/mL stock solution 
of the test compounds, which will give a final concentration of 100 μg/mL 
sample in 2% DMSO (Table 1). To the positive control wells (G1-6) and the 
negative control wells (H1-6), add 5 μL of the 20% DMSO solution.  
 
[Insert Table 1 around here] 
 
2. To wells G/H7-12, add 5 μL of the internal standard (e.g. staurosporine). 
3. Thaw a single tube of the enzyme (250 units per tube) and make up to 2 mL 
with the kinase reaction buffer to give a concentration of 125 units/mL. This 
will give a final concentration of 50 units/mL (or 2.50 units/well). 
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4. To six of the positive control wells (G1-6), add 20 μL of the reaction mixture 
containing 2.5 X the optimal concentration of kinase in kinase reaction buffer. 
The positive control should provide 100% luminescence. There will be 1880  
μL of this reaction mixture remaining.  
5. Add 20 μL of the kemptide (PKA peptide substrate, 10 mg/mL) to the 
remaining 1880 μL of kinase mixture. This will provide 200 μg of the kinase 
substrate in 1900 mL to give a 140 μM substrate/enzyme solution in buffer. 
This amount is sufficient for 1 x 96-well plate, giving a final concentration of 
56 μM in each well per 50 μL reaction. 
6. To all remaining wells, add 20 μL of the above reaction mixture (step 5) 
containing 2.5 X the optimal concentration of kinase and kinase substrate in 
1X kinase reaction buffer. (Negative controls, 0% luminescence). 
7. To all wells, add 25 μL of the ATP solution (20 μM, stock 3 ATP solution). 
This will give a final concentration of 10 μM in each well per 50 μL reaction. 
See Table 2 for a summary of the reagent volumes added to the 96-well plate.  
8. Using a plate shaker, gently shake the plate and incubate at room temperature 
for the optimal amount of time [see Note 10].  
9. Prepare Kinase-Glo® reagent: The kinase buffer should be stored in the 
freezer and thawed at room temperature. Add the Kinase-Glo® Substrate to the 
Kinase-Glo® Buffer and add 50 μL of this mixture to each well [see Note 11]. 
10. Mix the plate and incubate for 10 minutes at room temperature. Due to the 
long half-life of the Kinase-Glo® signal, the plates may be left longer before 
reading, if desired. Record luminescence, which will be directly proportional 
to percent inhibition of the controls [see Notes 12-14].  
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[Insert Table 2 around here] 
 
3.2 MTS Assay  
The MTS assay described here utilises Promega’s MTS CellTiter 96® AQueous One 
Solution Cell Proliferation assay and is performed according to the manufacturer’s 
instructions (30-31) .  
1. Determination of cell number and viability: Place 20 µL cells + 20 µL 
Trypan blue on parafilm and place 20 µL of this mixture under a cover-slip on 
the haemocytometer. Count the number of cells using the equation provided 
[see Note 15] to determine the volume required to get a cell concentration of 
111,000 cells/mL. 
2. Day 1 - Setting Up the Plate: Pipette 610 µL of cells (as determined in Step 1 
of the procedure) into a new Falcon tube and centrifuge at 1600 rpm for five 
min. (For four plates, pipette 2.44 mL of cells). 
3. Drain off supernatant and resuspend the pellet into 2.5 mL of media. This will 
give you 2.5 mL of cell solution at 111,000 cells/mL. (For four plates, you 
would resuspend in 10 mL of media).	
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4. Pipette 100 µL of media into wells A1-A12, H1-H12, B1-G1, B11-G11, B12-
G12, B5-B7, E5-E7, F5-F7 and G5-G7 as per Fig. 2. These wells are used as 
blanks to stop any interference that may occur when the spectrophotometer 
reads the absorbance values for the test wells. 	
[Insert Figure 2 near here]	
5. Pipette 90 µL of media into wells B8-G8, B9-G9, B10-G10. These wells will 
form the sample background controls.	
6. Pipette 90 µL of cell solution into wells B2-G2, B3-G3, B4-G4. These wells 
will form the sample wells.	
7. Pipette 90 µL of cell solution into wells D5-D7. These wells will form the 
2.5%  DMSO controls. 	
8. Pipette 100 µL of cell solution into wells C5-C7. These wells will form the 
cell controls.	
9.  Incubate plates for 24 hours at 37 ºC with 5% carbon dioxide (CO2).	
10.  Day Two - Diluting Test Compounds: Prepare a microtitre plate for serial 
dilutions of the test compounds as shown in Fig. 3 for each compound to be 
tested. Wells A3-G3 should all contain a final volume of 100 µL. 
[Insert Figure 3 near here] 
11. Adding serial dilutions of samples to cells: Using the plate of cells prepared 
on Day 1, pipette 10 µL of each sample dilution of the test compound in 25% 
DMSO (i.e. A3-F3, step 11) in triplicate into the 18 wells containing 90 µL of 
cell solution (i.e. 10 μL of the sample at 500 ug/mL in triplicate into wells B2-
B4, 250 ug/mL sample into C2-C4 etc, down to the 15.5 µg/mL sample into 
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G2-4). Repeat this step, by adding 10 µL of the serial dilutions of the sample 
in triplicate to the 18 wells containing 90 µL of media (e.g. wells B8-G8, B9-
G9, B10-G10). The test compounds will now have a final concentration of 
2.5% DMSO in all wells.  
12. Pipette 10 µL of the 0 µg/mL in 25% DMSO (i.e. G3 from step 11) into the 
three remaining wells containing 90 µL cells (wells D5-D7). This will be the 
2.5% DMSO control. 
13. Incubate plate for 24 hours at 37 ºC and 5% CO2 [see Note 16]. 
14. Day Three - Adding MTS Reagent and Plate Reading: Thaw MTS reagent 
before use (~1 mL MTS reagent required per plate). 
15. Pipette 20 µL of the MTS reagent into all sample wells (e.g. B2-G2, B3-G3, 
B4-G4, B5-D5, B6-D6, B7-G7, B8-G8, B9-G9, B10-G10) [see Note 17].  
16. Incubate for three hours at 37 ºC and 5% CO2. 
17. Wrap the plates in aluminium foil and take to the spectrophotometer. Read the 
absorbance of the whole plate at 490 nm [see Note 18]. 
 
4. Notes 
1. A final concentration of 2% DMSO was used for the sample and was found 
not to interfere with results at this concentration. Standards and controls used 
in the assay were also dissolved in a final concentration of 2% DMSO. Other 
solvents such as 2% ethanol can be used, provided all standards/controls are 
also prepared in this solvent. 
2. We found that a starting stock solution of 1 mg/mL of sample (diluted to 100 
µg/mL in the assay) was appropriate to identify kinase inhibitory activity. 
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Samples can be tested at lower concentrations or over a range of different 
concentrations to determine IC50 values. 
3. We found that it is best to prepare the buffer solution fresh each time and to 
store the buffer at room temperature. 
4. For kinases other than PKA, the optimum amount of kinase enzyme will need 
to be determined and the quantity of other reagents adjusted accordingly (28).  
5. Kemptide (PKA Peptide Substrate) is a synthetic peptide substrate for PKA 
derived from the PKA phosphorylation site in liver pyruvate kinase.  
6. This assay can be used to identify whether the kinase inhibitor is ATP 
competitive or non-competitive, by utilising various ratios of ATP (e.g. <10 
μM ATP for ATP-competitive inhibitors and >100 μM for ATP non-
competitive inhibitors). In general, we found it is best to prepare ATP 
solutions fresh, while the ATP reagent itself should be stored in the freezer. 
7. We include an internal reference of a known kinase inhibitor such as 
staurosporine in our assays (IC50 = 7 nM vs PKA; IC50 = 0.7 nM vs PKC ) by 
adding 5 μL of a 1 mg/mL solution of the inhibitor (in 20% DMSO) to six of 
the wells in place of a sample set. Staurosporine is a potent inhibitor of PKC 
and can induce apoptosis in Jurkat cells. Other PKA inhibitors include the 
isoquinoline sulfonamides H-9 (IC50 = 2 μM) and H-89 (IC50 = 48 nM). 
8. RPMI-1640 was developed by Moore et al. (32-33) at Roswell Park Memorial 
Institute. 
9. Human, leukemic, monocyte-like, histolytic lymphoma (U937) and human, 
metastatic breast adenocarcinoma (MDA-MB-231) cancer cells were obtained 
from American Type Culture Collection (ATCC, VA, USA) distributed by 
Cryosite, NSW, Australia. Cells were regularly cultured in vitro in culture 
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medium consisting of RPMI-1640 medium, along with 2 mM L-glutamine, 
5.6% (2 g/L) NaHCO3 and 5% foetal calf serum. The cells were maintained in 
a Huracell incubator (Kendro Laboratory Products, Langenselbold, Germany) 
at 37 °C with a humidified atmosphere containing 5% CO2. However, a wide 
range of both normal and cancer cell lines can be used in this assay.  
10. We found that thawing the Kinase-Glo® reagents (Kinase-Glo® substrate and 
Kinase-Glo® buffer) generally took one hour and we also allowed an hour for 
the incubation time. We strongly advise optimizing the kinase reaction 
conditions so that the reaction can be run at room temperature to avoid 
formation of temperature gradients. Information regarding optimization of 
kinase reaction conditions can be found in the manufacturer’s Technical 
Bulletin (28). 
11. The choice of Kinase-Glo® reagent will depend on the desired ATP 
concentration to be used in the assay. This information can be found in the 
manufacturer’s protocol, Promega Corporation, Australia (28,34). 
12. We find that it is best to read the plate within 15 mins after the addition of the 
Kinase-Glo® reaction mixture. 
13. Instrument settings depend on the manufacturer. An integration time of 0.25–1 
second per well should serve as a guideline. We found that the best plate 
reading is immediately after adding the Kinase-Glo® Buffer and when the 
incubation is performed at room temperature. 
14. The most common assay detection methods are colorimetric or fluorescence-
based. However, luminescent-based detection is particularly desirable for 
coloured products such as natural products, as coloured extracts and 
compounds can lead to false results when using absorbance as the end point. 
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Utilization of luminescence can be more beneficial for biological screening  
by identifying hits with a lower number of false positives (35). 
15. An example calculation of cell concentration of which the values obtained will 
be used in the method protocol described herein:  
. 	 	 	
#	 	 	 	4	
4
	 	2			 	10000	




	 	2	 	10000	 	455000	 	
Therefore, to get a cell concentration of 111,000 cells/mL, you will need: 
111000	 /
455000
	 	0.244	 	 	244	μ 	
For the preparation of one plate the cells will be resuspended in 2.5 mL media 
therefore the volume of cells required would be: 
244	μ 	 	2.5	 		610	μ  
Adjust accordingly if more plates are required.  
For example, the preparation of 4 plates will require: 
244	 	 	10	 	 2.5	 	 	 	 	4	 	 	2.44	 	
16.  Longer incubation times of 48 – 72 hours are also routinely employed in this 
assay. 
17. The MTS reagent is light sensitive so this step should be performed with the 
lights off in the cytotoxic cabinet. 
18. As this is a colorimetric assay, it should be kept in mind that both coloured 
compounds and natural product extracts may interfere with the absorbance 
reading, and appropriate background controls should always be performed. 
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Table 1 Kinase assay plate preparation: wells A-F[1-12] are the test compounds; 
wells G1-6 are positive controls; wells H1-6 are negative controls; and H7-12 and G7-
12 are internal reference standards (Std). The plate below shows the set-up for 12 test 
compounds run twice (samples a and b) in triplicate. This gives six data points per % 
inhibition reading. 
 1 2 3 4 5 6 7 8 9 10 11 12 
A 1a 1b 2a 2b 3a 3b 4a 4b 5a 5b 6a 6b 
B 1a 1b 2a 2b 3a 3b 4a 4b 5a 5b 6a 6b 
C 1a 1b 2a 2b 3a 3b 4a 4b 5a 5b 6a 6b 
D 7a 7b 8a 8b 9a 9b 10a 10b 11a 11b 12a 12b 
E 7a 7b 8a 8b 9a 9b 10a 10b 11a 11b 12a 12b 
F 7a 7b 8a 8b 9a 9b 10a 10b 11a 11b 12a 12b 
G Positive Control (100% Luminescence) Std1a Std1a Std1a Std2a Std2a Std2a 





















Sample  1 mg/mL - - - 100 
ug/mL 









140 μM 20 - 20 56 μM 
ATP solution (2X) 20 μM 25 25 25 10 μM 
Total reaction volume  50 50 50  
Kinase-Glo® reagent  50 50 50  
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Figure 3: Janice_McCauley_Figure_3.tif at 600 DPI 
 
Fig. 3. Preparation of microtitre plate for 1:2 serial dilutions. Add 100 µL of DMSO 
and 100 µL of the test compound (4 mg/mL in DMSO) to well A1. Next, add 100 µL 
of DMSO to wells B1 to G1. Then, 100 µL is transferred from A1 to B1; B1 to C1 
and so forth until F1, where 100 µL is removed and discarded. G1 should contain just 
100  μL of 100% DMSO. Next 50 µL of media is added to wells A2-G2 and A3-G3 
and 50 µL transferred from A1 to A2 and then from A2 to A3 to give 100 µL of the 
sample at a concentration of 500 μg/mL in 25% DMSO in media. This is repeated for 
wells B2-B3, C2-C3, etc to give a series of 1:2 dilutions of the sample.
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